Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children: A report from the Children's Oncology Group

Heidi Russell, J. Michael Swint, Lincy Lal, Jane L Meza, David Walterhouse, Douglas S. Hawkins, M. Fatih Okcu

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Recent Children's Oncology Group trials for low-risk rhabdomyosarcoma attempted to reduce therapy while maintaining excellent outcomes. D9602 delivered 45 weeks of outpatient vincristine and dactinomycin (VA) for patients in Subgroup A. ARST0331 reduced the duration of therapy to 22 weeks but added four doses of cyclophosphamide to VA for patients in Subset 1. Failure-free survival was similar. We undertook a cost minimization comparison to help guide future decision-making. Procedure: Addressing the costs of treatment from the healthcare perspective we modeled a simple decision-analytic model from aggregate clinical trial data. Medical care inputs and probabilities were estimated from trial reports and focused chart review. Costs of radiation, surgery and off-therapy surveillance were excluded. Unit costs were obtained from literature and national reimbursement and inpatient utilization databases and converted to 2012 US dollars. Model uncertainty was assessed with first-order sensitivity analysis. Results: Direct medical costs were $46,393 for D9602 and $43,261 for ARST0331 respectively, making ARST0331 the less costly strategy. Dactinomycin contributed the most to D9602 total costs but varied with age (42-69%). Chemotherapy administration costs accounted for the largest proportion of ARST0331 total costs (39-57%). ARST0331 incurred fewer costs than D9602 under most alternative distributive models and alternative clinical practice assumptions. Conclusions: Cost analysis suggests that ARST0331 may incur fewer costs than D9602 from the healthcare system's perspective. Attention to the services driving the costs provides directions for future efficiency improvements. Future studies should prospectively consider the patient and family's perspective. Pediatr Blood Cancer 2014;61:970-976.

Original languageEnglish (US)
Pages (from-to)970-976
Number of pages7
JournalPediatric Blood and Cancer
Volume61
Issue number6
DOIs
StatePublished - Jun 2014

Fingerprint

Rhabdomyosarcoma
Costs and Cost Analysis
Therapeutics
Dactinomycin
Health Care Costs
Vincristine
Cyclophosphamide
Uncertainty
Inpatients
Decision Making
Outpatients
Radiotherapy
Clinical Trials
Databases
Delivery of Health Care
Drug Therapy

Keywords

  • Childhood cancer
  • Cost analysis
  • Rhabdomyosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children : A report from the Children's Oncology Group. / Russell, Heidi; Swint, J. Michael; Lal, Lincy; Meza, Jane L; Walterhouse, David; Hawkins, Douglas S.; Okcu, M. Fatih.

In: Pediatric Blood and Cancer, Vol. 61, No. 6, 06.2014, p. 970-976.

Research output: Contribution to journalArticle

Russell, Heidi ; Swint, J. Michael ; Lal, Lincy ; Meza, Jane L ; Walterhouse, David ; Hawkins, Douglas S. ; Okcu, M. Fatih. / Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children : A report from the Children's Oncology Group. In: Pediatric Blood and Cancer. 2014 ; Vol. 61, No. 6. pp. 970-976.
@article{e31d98f8290c4b999dc166814bf094b9,
title = "Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children: A report from the Children's Oncology Group",
abstract = "Background: Recent Children's Oncology Group trials for low-risk rhabdomyosarcoma attempted to reduce therapy while maintaining excellent outcomes. D9602 delivered 45 weeks of outpatient vincristine and dactinomycin (VA) for patients in Subgroup A. ARST0331 reduced the duration of therapy to 22 weeks but added four doses of cyclophosphamide to VA for patients in Subset 1. Failure-free survival was similar. We undertook a cost minimization comparison to help guide future decision-making. Procedure: Addressing the costs of treatment from the healthcare perspective we modeled a simple decision-analytic model from aggregate clinical trial data. Medical care inputs and probabilities were estimated from trial reports and focused chart review. Costs of radiation, surgery and off-therapy surveillance were excluded. Unit costs were obtained from literature and national reimbursement and inpatient utilization databases and converted to 2012 US dollars. Model uncertainty was assessed with first-order sensitivity analysis. Results: Direct medical costs were $46,393 for D9602 and $43,261 for ARST0331 respectively, making ARST0331 the less costly strategy. Dactinomycin contributed the most to D9602 total costs but varied with age (42-69{\%}). Chemotherapy administration costs accounted for the largest proportion of ARST0331 total costs (39-57{\%}). ARST0331 incurred fewer costs than D9602 under most alternative distributive models and alternative clinical practice assumptions. Conclusions: Cost analysis suggests that ARST0331 may incur fewer costs than D9602 from the healthcare system's perspective. Attention to the services driving the costs provides directions for future efficiency improvements. Future studies should prospectively consider the patient and family's perspective. Pediatr Blood Cancer 2014;61:970-976.",
keywords = "Childhood cancer, Cost analysis, Rhabdomyosarcoma",
author = "Heidi Russell and Swint, {J. Michael} and Lincy Lal and Meza, {Jane L} and David Walterhouse and Hawkins, {Douglas S.} and Okcu, {M. Fatih}",
year = "2014",
month = "6",
doi = "10.1002/pbc.24950",
language = "English (US)",
volume = "61",
pages = "970--976",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children

T2 - A report from the Children's Oncology Group

AU - Russell, Heidi

AU - Swint, J. Michael

AU - Lal, Lincy

AU - Meza, Jane L

AU - Walterhouse, David

AU - Hawkins, Douglas S.

AU - Okcu, M. Fatih

PY - 2014/6

Y1 - 2014/6

N2 - Background: Recent Children's Oncology Group trials for low-risk rhabdomyosarcoma attempted to reduce therapy while maintaining excellent outcomes. D9602 delivered 45 weeks of outpatient vincristine and dactinomycin (VA) for patients in Subgroup A. ARST0331 reduced the duration of therapy to 22 weeks but added four doses of cyclophosphamide to VA for patients in Subset 1. Failure-free survival was similar. We undertook a cost minimization comparison to help guide future decision-making. Procedure: Addressing the costs of treatment from the healthcare perspective we modeled a simple decision-analytic model from aggregate clinical trial data. Medical care inputs and probabilities were estimated from trial reports and focused chart review. Costs of radiation, surgery and off-therapy surveillance were excluded. Unit costs were obtained from literature and national reimbursement and inpatient utilization databases and converted to 2012 US dollars. Model uncertainty was assessed with first-order sensitivity analysis. Results: Direct medical costs were $46,393 for D9602 and $43,261 for ARST0331 respectively, making ARST0331 the less costly strategy. Dactinomycin contributed the most to D9602 total costs but varied with age (42-69%). Chemotherapy administration costs accounted for the largest proportion of ARST0331 total costs (39-57%). ARST0331 incurred fewer costs than D9602 under most alternative distributive models and alternative clinical practice assumptions. Conclusions: Cost analysis suggests that ARST0331 may incur fewer costs than D9602 from the healthcare system's perspective. Attention to the services driving the costs provides directions for future efficiency improvements. Future studies should prospectively consider the patient and family's perspective. Pediatr Blood Cancer 2014;61:970-976.

AB - Background: Recent Children's Oncology Group trials for low-risk rhabdomyosarcoma attempted to reduce therapy while maintaining excellent outcomes. D9602 delivered 45 weeks of outpatient vincristine and dactinomycin (VA) for patients in Subgroup A. ARST0331 reduced the duration of therapy to 22 weeks but added four doses of cyclophosphamide to VA for patients in Subset 1. Failure-free survival was similar. We undertook a cost minimization comparison to help guide future decision-making. Procedure: Addressing the costs of treatment from the healthcare perspective we modeled a simple decision-analytic model from aggregate clinical trial data. Medical care inputs and probabilities were estimated from trial reports and focused chart review. Costs of radiation, surgery and off-therapy surveillance were excluded. Unit costs were obtained from literature and national reimbursement and inpatient utilization databases and converted to 2012 US dollars. Model uncertainty was assessed with first-order sensitivity analysis. Results: Direct medical costs were $46,393 for D9602 and $43,261 for ARST0331 respectively, making ARST0331 the less costly strategy. Dactinomycin contributed the most to D9602 total costs but varied with age (42-69%). Chemotherapy administration costs accounted for the largest proportion of ARST0331 total costs (39-57%). ARST0331 incurred fewer costs than D9602 under most alternative distributive models and alternative clinical practice assumptions. Conclusions: Cost analysis suggests that ARST0331 may incur fewer costs than D9602 from the healthcare system's perspective. Attention to the services driving the costs provides directions for future efficiency improvements. Future studies should prospectively consider the patient and family's perspective. Pediatr Blood Cancer 2014;61:970-976.

KW - Childhood cancer

KW - Cost analysis

KW - Rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84901710311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901710311&partnerID=8YFLogxK

U2 - 10.1002/pbc.24950

DO - 10.1002/pbc.24950

M3 - Article

C2 - 24453105

AN - SCOPUS:84901710311

VL - 61

SP - 970

EP - 976

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -